Vesugen is a short tripeptide (KED) that restores endothelial and neuronal gene expression, improving vascular elasticity and cognitive function. Used for hypertension, ischemia, and vascular aging.
Vesugen
Also known as: A-7 Vascular Endothelium Bioregulator Peptide
Overview
Benefits
- Enhances nitric oxide
- Reduces endothelial inflammation
- Improves vascular elasticity
- Boosts perfusion
- Supports cognition
Consider This Peptide If You Want To
- Improve vascular and cognitive health
- Reduce oxidative vascular stress
Dosage & Administration
Dosage Guidelines
Recommended Dosage
• Amount:20 mg
• Frequency:daily
• Duration:4 weeks
• Rest Period:12 weeks
• Time of Day:morning
• Ingestion:oral
Best taken on an empty stomach with water. Sublingual administration may provide faster absorption. Monitor blood pressure in sensitive individuals.
Administration Routes:SublingualOral CapsuleSubcutaneous Injection
Research Findings on Dosage:
Sublingual Administration
• Commonly Reported Dosage: 5--6 drops under the tongue, 3--4 times daily
• Duration: 1 month; repeat every 3--6 months
• Administration Notes: Best taken 10--15 minutes before meals. Sublingual dosing is preferred for rapid systemic absorption. Refrigerate after opening.
Oral Capsule Administration
• Commonly Reported Dosage: 1--2 capsules (0.215 g each), once or twice daily (20-40 mg of peptide complex A-7)
• Duration: 30-day cycle; repeat every 3--6 months
• Administration Notes: Take with water on an empty stomach. Anecdotal reports suggest improvements in extremity circulation and cognitive clarity within 2--4 weeks.
Subcutaneous Injection
• Commonly Reported Dosage: 2 mg AM/PM
• Duration: 30 days; 2 months off, repeat 2-3x per year
Mechanism of Action
Mechanism of Action
How this peptide works in the body
Restoration of Endothelial Gene Expression
Vesugen enhances transcription of eNOS, KLF2, and VE-cadherin genes through increased H3K4 methylation and reduced promoter methylation. These modifications upregulate endothelial nitric oxide production, improve intercellular junctions, and restore vasodilatory tone. It also increases expression of SIRT1, which maintains endothelial homeostasis under oxidative stress.
Suppression of Vascular Inflammation and Immune Infiltration
The peptide inhibits NF-κB and STAT3 signaling in vascular endothelial cells, decreasing VCAM-1, ICAM-1, and selectin expression. This limits leukocyte adhesion and trans-endothelial migration. Concurrently, it enhances IL-10 and heme oxygenase-1 (HO-1) expression, reducing local oxidative damage and inflammatory infiltration.
Support of Extracellular Matrix Integrity and Vascular Elasticity
Vesugen upregulates elastin and collagen type IV expression while modulating MMP-2 and TIMP-1 balance. This preserves structural integrity of vessel walls and prevents pathological remodeling. TGF-β and SMAD2/3 pathway activation supports healthy ECM turnover, reducing fibrosis and arterial stiffening.
Stimulation of Angiogenesis and Microvascular Recovery
The peptide increases VEGF-A and angiopoietin-1 expression, enhancing neovascularization in ischemic tissues. It promotes EPC (endothelial progenitor cell) mobilization via upregulation of CXCR4 and SDF-1, improving capillary density and oxygen delivery. Controlled angiogenic activation supports tissue repair without triggering aberrant vessel formation.
Consider Stacking With
- Ventfort
- Epitalon
- Svetinorm
- Thymalin
- Endoluten
Side Effects & Cautions
Common Side Effects
- None common
Cautions
- Caution with vasodilators or low BP
Rare Side Effects
- Mild hypotension or dizziness
Research & References
Research Highlights
Khavinson et al., 2003: Reported restoration of endothelial function and reduced oxidative stress in aged rodents
Morozov et al., 2010: Demonstrated improved capillary perfusion and decreased vascular permeability
Trofimova et al., 2015: Observed blood pressure normalization and reduced endothelial biomarkers in hypertensive patients
Linkova et al., 2016: Showed increased EPC activity and angiogenesis in vascular injury models
References
Khavinson V, et al. "Peptide bioregulation of vascular endothelium." Biogerontology. 2003.
Morozov VG, et al. "Vesugen and microvascular health in aging." Int J Mol Med. 2010.
Trofimova SV, et al. "Peptide-based endothelial recovery in hypertensive pathology." Clin Cardiol. 2015.
Linkova NS, et al. "Endothelial progenitor activation by vascular peptides." J Vasc Biol. 2016.